Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed the results of an interim analysis from a second Phase 3 trial investigating the use of the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir.
Lenacapavir reduced HIV infections by 96% compared to background HIV incidence (bHIV).
There were two incident cases among 2,180 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group.
Twice-yearly lenacapavir also demonstrated superiority to once-daily Gilead’s Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg; F/TDF).
There were nine incident cases among 1,087 individuals in the Truvada group (incidence 0.93 per 100 person-years).
Twice-yearly lenacapavir was ...
